EA000763B1 - Способ минимизации остеопороза - Google Patents

Способ минимизации остеопороза Download PDF

Info

Publication number: EA000763B1
Authority: EA; Eurasian Patent Office
Prior art keywords: compound; formula; pharmaceutically acceptable; acceptable salt; pyrrolidinyl
Prior art date: 1995-06-06

Application number

EA199800013A

Other languages

English (en)

Russian (ru)

Other versions

EA199800013A1 (ru

Inventor

Джордж Дж. Каллинан

Стивен А. Фонтана

Original Assignee

Эли Лилли Энд Компани

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-06

Filing date

1996-06-05

Publication date

2000-04-24

1996-06-05 Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани

1998-06-25 Publication of EA199800013A1 publication Critical patent/EA199800013A1/ru

2000-04-24 Publication of EA000763B1 publication Critical patent/EA000763B1/ru

Links

238000000034 method Methods 0.000 title claims abstract description 35
206010065687 Bone loss Diseases 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 claims abstract description 37
210000000988 bone and bone Anatomy 0.000 claims abstract description 33
208000001132 Osteoporosis Diseases 0.000 claims abstract description 27
-1 methyl-1-pyrrolidinyl Chemical group 0.000 claims abstract description 24
150000003839 salts Chemical class 0.000 claims abstract description 23
102000003982 Parathyroid hormone Human genes 0.000 claims abstract description 18
108090000445 Parathyroid hormone Proteins 0.000 claims abstract description 18
239000000199 parathyroid hormone Substances 0.000 claims abstract description 18
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
241000124008 Mammalia Species 0.000 claims abstract description 14
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims abstract description 13
201000009273 Endometriosis Diseases 0.000 claims abstract description 11
239000003085 diluting agent Substances 0.000 claims abstract description 9
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims abstract description 9
125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims abstract description 6
239000003937 drug carrier Substances 0.000 claims abstract description 6
239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 4
XSXHWVKGUXMUQE-UHFFFAOYSA-N osmium dioxide Inorganic materials O=[Os]=O XSXHWVKGUXMUQE-UHFFFAOYSA-N 0.000 claims abstract 3
230000001195 anabolic effect Effects 0.000 claims description 24
229960001319 parathyroid hormone Drugs 0.000 claims description 5
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
239000003263 anabolic agent Substances 0.000 abstract description 9
229940124325 anabolic agent Drugs 0.000 abstract description 7
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract description 3
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract description 3
POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 51
229960000766 danazol Drugs 0.000 description 51
239000002552 dosage form Substances 0.000 description 19
239000000203 mixture Substances 0.000 description 14
239000004615 ingredient Substances 0.000 description 13
229960004622 raloxifene Drugs 0.000 description 13
GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 13
239000002775 capsule Substances 0.000 description 12
239000003826 tablet Substances 0.000 description 11
229920002472 Starch Polymers 0.000 description 9
230000000694 effects Effects 0.000 description 9
235000019698 starch Nutrition 0.000 description 9
229940011871 estrogen Drugs 0.000 description 8
239000000262 estrogen Substances 0.000 description 8
239000008107 starch Substances 0.000 description 8
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
239000004480 active ingredient Substances 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
239000006188 syrup Substances 0.000 description 6
235000020357 syrup Nutrition 0.000 description 6
238000002560 therapeutic procedure Methods 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
239000000843 powder Substances 0.000 description 5
239000000243 solution Substances 0.000 description 5
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
239000001768 carboxy methyl cellulose Substances 0.000 description 4
239000007903 gelatin capsule Substances 0.000 description 4
239000008177 pharmaceutical agent Substances 0.000 description 4
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 4
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 4
229920000168 Microcrystalline cellulose Polymers 0.000 description 3
125000000217 alkyl group Chemical group 0.000 description 3
230000001833 anti-estrogenic effect Effects 0.000 description 3
230000003111 delayed effect Effects 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
230000009969 flowable effect Effects 0.000 description 3
239000012530 fluid Substances 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
235000019813 microcrystalline cellulose Nutrition 0.000 description 3
239000008108 microcrystalline cellulose Substances 0.000 description 3
229940016286 microcrystalline cellulose Drugs 0.000 description 3
229920001296 polysiloxane Polymers 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
239000001267 polyvinylpyrrolidone Substances 0.000 description 3
229920002545 silicone oil Polymers 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
235000012222 talc Nutrition 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
239000001993 wax Substances 0.000 description 3
239000005711 Benzoic acid Substances 0.000 description 2
208000017667 Chronic Disease Diseases 0.000 description 2
208000017701 Endocrine disease Diseases 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
229920000084 Gum arabic Polymers 0.000 description 2
235000010489 acacia gum Nutrition 0.000 description 2
229940070021 anabolic steroids Drugs 0.000 description 2
229940046836 anti-estrogen Drugs 0.000 description 2
235000010233 benzoic acid Nutrition 0.000 description 2
239000000969 carrier Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000002591 computed tomography Methods 0.000 description 2
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
230000000593 degrading effect Effects 0.000 description 2
239000000328 estrogen antagonist Substances 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
230000014509 gene expression Effects 0.000 description 2
239000008187 granular material Substances 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
238000009806 oophorectomy Methods 0.000 description 2
210000004197 pelvis Anatomy 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
229960002119 raloxifene hydrochloride Drugs 0.000 description 2
BKXVVCILCIUCLG-UHFFFAOYSA-N raloxifene hydrochloride Chemical compound [H+].[Cl-].C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 BKXVVCILCIUCLG-UHFFFAOYSA-N 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
235000006491 Acacia senegal Nutrition 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 1
108060003393 Granulin Proteins 0.000 description 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
206010030247 Oestrogen deficiency Diseases 0.000 description 1
LCYXYLLJXMAEMT-SAXRGWBVSA-N Pyridinoline Chemical compound OC(=O)[C@@H](N)CCC1=C[N+](C[C@H](O)CC[C@H](N)C([O-])=O)=CC(O)=C1C[C@H](N)C(O)=O LCYXYLLJXMAEMT-SAXRGWBVSA-N 0.000 description 1
241000700159 Rattus Species 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
206010047486 Virilism Diseases 0.000 description 1
238000002441 X-ray diffraction Methods 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000000556 agonist Substances 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000001548 androgenic effect Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000037182 bone density Effects 0.000 description 1
210000002805 bone matrix Anatomy 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
235000012241 calcium silicate Nutrition 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
229940109239 creatinine Drugs 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
102000015694 estrogen receptors Human genes 0.000 description 1
108010038795 estrogen receptors Proteins 0.000 description 1
CHNXZKVNWQUJIB-CEGNMAFCSA-N ethisterone Chemical class O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 CHNXZKVNWQUJIB-CEGNMAFCSA-N 0.000 description 1
239000000945 filler Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
230000036449 good health Effects 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229960002591 hydroxyproline Drugs 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000002513 implantation Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000011344 liquid material Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
231100000794 masculinization Toxicity 0.000 description 1
239000000463 material Substances 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000009245 menopause Effects 0.000 description 1
230000027939 micturition Effects 0.000 description 1
239000011707 mineral Substances 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
230000011164 ossification Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
238000004321 preservation Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000003825 pressing Methods 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
LZFIOSVZIQOVFW-UHFFFAOYSA-N propyl 2-hydroxybenzoate Chemical class CCCOC(=O)C1=CC=CC=C1O LZFIOSVZIQOVFW-UHFFFAOYSA-N 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
239000008213 purified water Substances 0.000 description 1
238000011552 rat model Methods 0.000 description 1
239000012056 semi-solid material Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000011343 solid material Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000012058 sterile packaged powder Substances 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
230000037317 transdermal delivery Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Obesity (AREA)
Diabetes (AREA)
Hematology (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Nutrition Science (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Control Of Motors That Do Not Use Commutators (AREA)
Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
Glass Compositions (AREA)

EA199800013A 1995-06-06 1996-06-05 Способ минимизации остеопороза EA000763B1 (ru)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/467,475 US5599822A (en)	1995-06-06	1995-06-06	Methods for minimizing bone loss
PCT/US1996/008875 WO1996039138A1 (fr)	1995-06-06	1996-06-05	Procedes pour minimiser les pertes osseuses

Publications (2)

Publication Number	Publication Date
EA199800013A1 EA199800013A1 (ru)	1998-06-25
EA000763B1 true EA000763B1 (ru)	2000-04-24

Family

ID=23855853

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EA199800013A EA000763B1 (ru)	1995-06-06	1996-06-05	Способ минимизации остеопороза

Country Status (22)

Country	Link
US (1)	US5599822A (fr)
EP (1)	EP0747054B1 (fr)
JP (1)	JPH11507051A (fr)
KR (1)	KR19990022498A (fr)
CN (1)	CN1192145A (fr)
AU (1)	AU696209B2 (fr)
BR (1)	BR9608389A (fr)
CA (1)	CA2223055A1 (fr)
CO (1)	CO4700446A1 (fr)
CZ (1)	CZ382997A3 (fr)
DE (1)	DE69623074T2 (fr)
EA (1)	EA000763B1 (fr)
ES (1)	ES2181849T3 (fr)
HU (1)	HUP9900849A3 (fr)
IL (1)	IL118590A (fr)
NO (1)	NO975581L (fr)
PL (1)	PL323935A1 (fr)
TR (1)	TR199701507T1 (fr)
TW (1)	TW372969B (fr)
WO (1)	WO1996039138A1 (fr)
YU (1)	YU34396A (fr)
ZA (1)	ZA964778B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9702401D0 (sv) *	1997-06-19	1997-06-19	Astra Ab	Pharmaceutical use
US6096764A (en) *	1997-08-21	2000-08-01	Eli Lilly And Company	Methods for inhibiting detrimental side-effects due to GnRH of GnRH agonist administration
DE19825591A1 (de) *	1998-06-09	1999-12-23	Jenapharm Gmbh	Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata
AU7993500A (en) *	1999-11-15	2001-05-30	New Millennium Pharmaceutical Research, Inc.	Intranasal administration of raloxifene and tamoxifen
EP1113007A1 (fr) *	1999-12-24	2001-07-04	Pfizer Inc.	Composés de tétrahydroisoquinoline comme agonistes/antagonistes d'oestrogène
US20050124537A1 (en) *	2000-04-27	2005-06-09	Amgen Inc.	Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US6756480B2 (en) *	2000-04-27	2004-06-29	Amgen Inc.	Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
EP1180364A1 (fr) *	2000-08-15	2002-02-20	Octagene GmbH	Hormones stéroidiennes comme agents de transfert
DE60327931D1 (de)	2002-07-22	2009-07-23	Lilly Co Eli	Selektive östrogenrezeptor modulatoren, die eine phenylsulfonyl-gruppe enthalten
CN101151048A (zh)	2004-05-10	2008-03-26	纳斯泰克制药公司	增强甲状旁腺激素粘膜递送的组合物和方法
JP5007427B2 (ja) *	2004-05-13	2012-08-22	アルザコーポレイション	副甲状腺ホルモン剤の経皮送達のための装置および方法
AU2006299887A1 (en) *	2005-10-06	2007-04-19	Nastech Pharmaceutical Company Inc.	PTH formulations and methods of use
WO2007044375A2 (fr) *	2005-10-06	2007-04-19	Nastech Pharmaceutical Company Inc.	Formulations pth et procédés d'utilisation
US11253498B2 (en) *	2017-06-01	2022-02-22	Nexyon Biotech Co., Ltd.	Pharmaceutical composition for treatment of bone-related disease
CN108785264A (zh) *	2018-07-03	2018-11-13	威海贯标信息科技有限公司	一种达那唑片剂组合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4133814A (en) *	1975-10-28	1979-01-09	Eli Lilly And Company	2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) *	1981-04-03	1983-04-19	Eli Lilly And Company	Synthesis of acylated benzothiophenes
US4418068A (en) *	1981-04-03	1983-11-29	Eli Lilly And Company	Antiestrogenic and antiandrugenic benzothiophenes
US5393763A (en) *	1992-07-28	1995-02-28	Eli Lilly And Company	Methods for inhibiting bone loss

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3135743A (en) *	1960-06-29	1964-06-02	Sterling Drug Inc	Steroido[2. 3-d]isoxazoles and preparation thereof
US5075321A (en) *	1987-03-24	1991-12-24	University Of Pennsylvania	Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes

1995
- 1995-06-06 US US08/467,475 patent/US5599822A/en not_active Expired - Fee Related
1996
- 1996-06-05 KR KR1019970708979A patent/KR19990022498A/ko not_active Withdrawn
- 1996-06-05 CZ CZ973829A patent/CZ382997A3/cs unknown
- 1996-06-05 CA CA002223055A patent/CA2223055A1/fr not_active Abandoned
- 1996-06-05 JP JP9501343A patent/JPH11507051A/ja active Pending
- 1996-06-05 WO PCT/US1996/008875 patent/WO1996039138A1/fr not_active Ceased
- 1996-06-05 HU HU9900849A patent/HUP9900849A3/hu unknown
- 1996-06-05 BR BR9608389A patent/BR9608389A/pt unknown
- 1996-06-05 TR TR97/01507T patent/TR199701507T1/xx unknown
- 1996-06-05 YU YU34396A patent/YU34396A/sh unknown
- 1996-06-05 AU AU60430/96A patent/AU696209B2/en not_active Ceased
- 1996-06-05 CO CO96029177A patent/CO4700446A1/es unknown
- 1996-06-05 PL PL96323935A patent/PL323935A1/xx unknown
- 1996-06-05 CN CN96195975A patent/CN1192145A/zh active Pending
- 1996-06-05 EA EA199800013A patent/EA000763B1/ru not_active IP Right Cessation
- 1996-06-06 TW TW085106756A patent/TW372969B/zh active
- 1996-06-06 ES ES96304180T patent/ES2181849T3/es not_active Expired - Lifetime
- 1996-06-06 EP EP96304180A patent/EP0747054B1/fr not_active Expired - Lifetime
- 1996-06-06 ZA ZA9604778A patent/ZA964778B/xx unknown
- 1996-06-06 DE DE69623074T patent/DE69623074T2/de not_active Expired - Fee Related
- 1996-06-06 IL IL11859096A patent/IL118590A/xx not_active IP Right Cessation
1997
- 1997-12-03 NO NO975581A patent/NO975581L/no not_active Application Discontinuation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4133814A (en) *	1975-10-28	1979-01-09	Eli Lilly And Company	2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) *	1981-04-03	1983-04-19	Eli Lilly And Company	Synthesis of acylated benzothiophenes
US4418068A (en) *	1981-04-03	1983-11-29	Eli Lilly And Company	Antiestrogenic and antiandrugenic benzothiophenes
US5393763A (en) *	1992-07-28	1995-02-28	Eli Lilly And Company	Methods for inhibiting bone loss

Also Published As

Publication number	Publication date
DE69623074D1 (de)	2002-09-26
YU34396A (sh)	1999-07-28
ZA964778B (en)	1997-12-08
BR9608389A (pt)	1999-05-04
HUP9900849A3 (en)	1999-11-29
ES2181849T3 (es)	2003-03-01
WO1996039138A1 (fr)	1996-12-12
EA199800013A1 (ru)	1998-06-25
CA2223055A1 (fr)	1996-12-12
HUP9900849A2 (hu)	1999-09-28
US5599822A (en)	1997-02-04
TR199701507T1 (xx)	1998-02-21
EP0747054A3 (fr)	1997-03-05
NO975581D0 (no)	1997-12-03
IL118590A0 (en)	1996-10-16
CO4700446A1 (es)	1998-12-29
IL118590A (en)	1999-10-28
NO975581L (no)	1997-12-03
AU696209B2 (en)	1998-09-03
AU6043096A (en)	1996-12-24
EP0747054A2 (fr)	1996-12-11
PL323935A1 (en)	1998-04-27
EP0747054B1 (fr)	2002-08-21
KR19990022498A (ko)	1999-03-25
CN1192145A (zh)	1998-09-02
DE69623074T2 (de)	2003-05-08
CZ382997A3 (cs)	1998-09-16
JPH11507051A (ja)	1999-06-22
TW372969B (en)	1999-11-01

Legal Events

Date	Code	Title	Description
2001-02-26	MM4A	Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)	Designated state(s): AM AZ BY KZ KG MD TJ TM RU

Publication	Publication Date	Title
RU2402331C2 (ru)	2010-10-27	Дроспиренон для гормональной заместительной терапии
RU2157203C2 (ru)	2000-10-10	Применение 2-фенил-3-ароилбензотиофенов для ингибирования эндометриоза
KR0161300B1 (ko)	1998-12-01	뼈 손실 예방에 유용한 벤조티오펜
KR100849919B1 (ko)	2008-08-04	에스트로겐 대체 요법으로 치료중인 여성의 호르몬결핍증을 치료하기 위한 에스트로겐 및 안드로겐의 조합
CA2138100A1 (fr)	1995-06-22	Methodes de traitement des symptomes menstruels et compositions a utiliser a cette fin
JPH10513152A (ja)	1998-12-15	抗黄体ホルモンおよびプロゲスチンを含有する周期相ホルモン養生法
US5446053A (en)	1995-08-29	Methods of inhibiting dysfunctional uterine bleeding
EP0747054B1 (fr)	2002-08-21	Méthodes pour diminuer la perte osseuse
JPH07196500A (ja)	1995-08-01	閉経期後症候群に関連する血管運動症状および併発性心理的障害を抑制するための医薬組成物
JPH08231394A (ja)	1996-09-10	骨損失抑制用製剤
US5637598A (en)	1997-06-10	Methods of inhibiting bone loss
EP0747056B1 (fr)	1999-12-15	Diminuer la perte osseuse par des combinaisons d'anti-estrogènes
KR20010052852A (ko)	2001-06-25	근골격 허약을 치료하기 위한 선택적인 에스트로겐 수용체조절제 및 성장 호르몬 분비촉진제의 치료적 혼합물
EP0771201B1 (fr)	2001-04-18	Utilisation des 2-phenyle-3-aroylbenzothiophenes pour la preparation d'un medicament pour l'empechement de l'hyperplasie endometriale primaire
JP2000159689A (ja)	2000-06-13	月経異常の処置又は予防剤
JP2000159688A (ja)	2000-06-13	子宮内膜症の処置又は予防剤